熱門資訊> 正文
癫痫研究取得积极结果后Ovid上升
2025-10-03 21:26
- Ovid Therapeutics (NASDAQ:OVID) stock rose after encouraging results from its early stage study testing its experimental candidate, OV329, aimed at treating drug-resistant epilepsy.
- Stock is up 24% premarket.
- The results of the study showed that OV329 significantly inhibits GABA-AT, as evidenced by various measurements.
- In the study, OV329 demonstrated a favorable safety and tolerability profile, with all potentially treatment-related adverse events reported as mild and transient.
- Looking ahead, Ovid plans to move OV329 into a Phase 2a trial targeting drug-resistant focal onset seizures.
- Additionally, the company is set to complete a final study to support regulatory submissions for its first oral KCC2 direct activator, OV4071, anticipated in early 2026.
More on Ovid Therapeutics
- Ovid Therapeutics jumps 28% on $175M private placement
- Seeking Alpha’s Quant Rating on Ovid Therapeutics
- Historical earnings data for Ovid Therapeutics
- Financial information for Ovid Therapeutics
推薦文章
美股機會日報 | 26年延續漲勢？美股獲華爾街齊聲唱多；金銀價格齊創新高，礦業股盤前普漲
AI熱潮推動，美國十大科技富豪淨資產今年增加逾5500億美元，馬斯克身價達6450億美元
銅價繼續狂飆創16年來最大漲幅！2026年供應「地震」持續引爆
年終盤點 | 2025資產回顧與展望：白銀暴賺146%力壓黃金成年度王者，港股牛市信心迴歸年漲28%，美股靠AI續創新高
現貨黃金和白銀價格升至歷史新高 受地緣政治和美元走軟影響
年終盤點 | 2025年十大牛熊財報震撼市場！甲骨文引爆AI投資狂潮，英偉達交出「逆天」財報后樂極生悲？
港股周報 | 高盛稱中國股市「牛市」格局不改！芯片行業利好頻傳，中芯國際周漲超9%；港股「英偉達」壁仞科技將於下周上市
年終盤點 | 極限施壓、反覆橫跳、瘋狂「搞事」痛擊全球股市！一文盤點特朗普年內「逆天」操作
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
